SYHA 1813
Alternative Names: SYHA-1813Latest Information Update: 11 Dec 2023
At a glance
- Originator Shanghai Institute of Materia Medica
- Developer Shanghai Runshi Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 Dec 2023 358320 CTP push: FET added, CTP linked (QC feedback incorporated)
- 06 Dec 2023 Shanghai Runshi Pharmaceutical plans a phase I pharmacokinetics and safety trial (In volunteers) in December 2023 (PO, Solution) (NCT06157918)
- 20 Oct 2023 Efficacy and adverse events data from phase I trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)